Uganda Sickle Surveillance Study (US-3)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 12
SponsorChildren's Hospital Medical Center, Cincinnati

About this trial

It is estimated that over 250,000 babies are born with sickle cell disease (SCD) annually in sub-Saharan Africa, and only 10% - 50% of them survive beyond five years of age. Data describing the magnitude of the sickle cell problem are lacking in most African countries. The available data on prevalence were mainly from older studies and small numbers of hospitalized patients. In Uganda, approximately 25,000 children are born with SCD but 70-80% die before their 5th birthday. Lehmann and Raper found 'sicklaemia' prevalence of 0.8% and 45% in the Sebei and Bambaa ethnic groups, respectively. A recent study found a SCT and SCD prevalence of 3% - 19% and 0% - 3%, respectively but this study addressed only 5 of Uganda's 111 districts and used a small convenience sample of children aged 6 - 60 months. The objective of this study is to determine the prevalence and map out the burden of SCT and SCD in Uganda.

Eligibility criteria

Qualifiers

Up to 1,000,000 samples may be collected during 2015 - 2030 following primary analysis based on surveillance findings.

Disqualifiers

Repeat samples on the same individuals during the study period will be excluded.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Children's Hospital Medical Center, Cincinnati

Lead sponsor

Makerere University

Collaborator

Ministry of Health, Uganda

Collaborator

Mulago Hospital, Uganda

Collaborator